Amarin Corporation (AMRN) Proxy Filing summary

Executive summary

• 2024 focused on operational momentum, new CEO appointment, and commercial strategy in Europe, with $200M+ revenue, $294M cash, and no debt at year-end.

• Board and management prioritize unlocking global potential for VASCEPA/VAZKEPA, especially in Europe and ROW, maintaining financial discipline and readiness for a U.S. authorized generic launch.

• Recent board changes include the appointment of Michael Torok following engagement with a shareholder group, and all directors now stand for annual re-election.

Voting matters and shareholder proposals

• Shareholders will vote on re-election of nine directors, advisory say-on-pay, auditor appointment, authority to allot shares, and disapplication of pre-emption rights.

• Proposal 13 adds Michael Torok for re-election following his recent board appointment.

• Board recommends voting FOR all nominees and proposals.

Board of directors and corporate governance

• Board comprises a majority of independent directors, with only the CEO considered non-independent.

• All key committees (Audit, Remuneration, Nominating & Corporate Governance) are composed solely of independent directors.

• Board eliminated classified structure; all directors now stand for annual re-election.

• Code of Conduct updated in July 2024; waivers require board or committee approval.

• Stock ownership guidelines in place for directors and executives.